Chitosan-lactobionic acid-thioctic acid-modified hollow mesoporous silica composite loaded with carborane for boron neutron capture therapy of hepatocellular carcinoma

Zhang, Taofeng; Xu, Dan; Yi, Yangman; Wang, Yu; Cui, Zhencun; Chen, Xiujuan; Ma, Qianlong; Song, Fuqiang; Zhu, Bowu; Zhao, Zhongfang; Cao, Judong; He, Dengfa; Chen, Ximeng; Liu, Bin

doi:10.1016/j.matdes.2022.111196

Cited by 7 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the number of electrons in the skeleton and different molecular structure, it can be classified into a few different types, such as closo-carborane, nido-carborane, arachno-carborane, etc., which have unique chemical properties and are quite different from traditional hydrocarbons. Carborane and its derivatives have high boron atom content, which contain 10-21 boron atoms in a single molecule, after further functionalization, carborane can be regarded as one of the most ideal choices of boron carriers in BNCT 48 , 49 . The ultra-small size and magnetic properties of magnetic nanomaterials represented by metal nanoparticles and metal nanotubes make them suitable for intravenous administration.…”

Section: Boron-containing Nct Nanomedicinementioning

confidence: 99%

Recent progress of nano-drugs in neutron capture therapy

Zhou,

Cheng,

Liu

et al. 2024

Theranostics

View full text Add to dashboard Cite

As a developing radiation treatment for tumors, neutron capture therapy (NCT) has less side effects and a higher efficacy than conventional radiation therapy. Drugs with specific isotopes are indispensable counterparts of NCT, as they are the indespensable part of the neutron capture reaction. Since the creation of the first and second generations of boron-containing reagents, NCT has significantly advanced. Notwithstanding, the extant NCT medications, predominantly comprised of small molecule boron medicines, have encountered challenges such monofunctionality, inadequate targeting of tumors, and hypermetabolism. There is an urgent need to promote the research and development of new types of NCT drugs. Bio-nanomaterials can be introduced into the realm of NCT, and nanotechnology can give conventional medications richer functionality and significant adaptability. This can complement the advantages of each other and is expected to develop more new drugs with less toxicity, low side effects, better tumor targeting, and high biocompatibility. In this review, we summarized the research progress of nano-drugs in NCT based on the different types and sources of isotopes used, and introduced the attempts and efforts made by relevant researchers in combining nanomaterials with NCT, hoping to provide pivotal references for promoting the development of the field of tumor radiotherapy.

show abstract

Section: Boron-containing Nct Nanomedicinementioning

confidence: 99%

Recent progress of nano-drugs in neutron capture therapy

Zhou,

Cheng,

Liu

et al. 2024

Theranostics

View full text Add to dashboard Cite

show abstract

“…Zhang et al reported the preparation of doxorubicin-conjugated 10 B 4 C nanoparticles, which could be used to combine BNCT and chemotherapy [ 46 ]. Zhang et al reported the preparation of a chitosan-lactobionic acid-thioctic acid-modified hollow mesoporous silica composite loaded with carborane (HMSN-S-S-CS-LA-TA) and its therapeutic effect on hepatocellular carcinoma [ 47 ].…”

Section: Recent Development and The Challengesmentioning

confidence: 99%

A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China

Zhang

Chong

Liu

et al. 2023

Cancers

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and neutron irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by the development of compact neutron source devices. The availability, ease of operation, and cost-effectiveness offered by these compact neutron sources make BNCT more accessible to cancer treatment centers. Two compact neutron sources, one being miniature reactor-based (IHNI-1) and the other one being accelerator-based (NeuPex), have entered the clinical research phase and are planned for medical device registration. Moreover, several accelerator-based neutron source devices employing different technical routes are currently under construction, further expanding the options for BNCT implementation. In addition, the development of compact neutron sources serves as an experimental platform for advancing the development of new boron agents. Several research teams are actively involved in the development of boron agents. Various types of third-generation boron agents have been tested and studied in vitro and in vivo. Compared to other radiotherapy therapies, BNCT in mainland China still faces specific challenges due to its limited clinical trial data and its technical support in a wide range of professional fields. To facilitate the widespread adoption of BNCT, it is crucial to establish relevant technical standards for neutron devices, boron agents, and treatment protocols.

show abstract

“…Dendritic MSN decorated with PEG-cDRG and carborane moieties, and pored-loaded with doxorubicin, was synthetized in 2021 [185] 32 (Figure 13). HMSN was covalently modified with chitosan (CS), lactobionic (LA) and thioctic (TA) acids, which can target asialoglycoprotein receptors that are over-expressed in hepatocellular carcinomas [186]. Pristine ortho-carborane was added to the HMSN-CS-LA-TA composite, and BNCT in vivo experiments resulted in an effective treatment of hepatocellular carcinoma.…”

Section: Nanoparticlesmentioning

confidence: 99%

In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection

Marforio,

Carboni,

Calvaresi

2023

Cancers

View full text Add to dashboard Cite

Carboranes have emerged as one of the most promising boron agents in boron neutron capture therapy (BNCT). In this context, in vivo studies are particularly relevant, since they provide qualitative and quantitative information about the biodistribution of these molecules, which is of the utmost importance to determine the efficacy of BNCT, defining their localization and (bio)accumulation, as well as their pharmacokinetics and pharmacodynamics. First, we gathered a detailed list of the carboranes used for in vivo studies, considering the synthesis of carborane derivatives or the use of delivery system such as liposomes, micelles and nanoparticles. Then, the formulation employed and the cancer model used in each of these studies were identified. Finally, we examined the analytical aspects concerning carborane detection, identifying the main methodologies applied in the literature for ex vivo and in vivo analysis. The present work aims to identify the current strengths and weakness of the use of carboranes in BNCT, establishing the bottlenecks and the best strategies for future applications.

show abstract

Chitosan-lactobionic acid-thioctic acid-modified hollow mesoporous silica composite loaded with carborane for boron neutron capture therapy of hepatocellular carcinoma

Cited by 7 publications

References 37 publications

Recent progress of nano-drugs in neutron capture therapy

Recent progress of nano-drugs in neutron capture therapy

A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China

In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection

Contact Info

Product

Resources

About